Indian Biosimilars: Going Global
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in…
Address: W-199-E, MIDC Khairne, Thane Belapur Road,Navi Mumbai – 400705.,India
Tel: +91-22-4151 5151
Web: http://www.nilsan-nishotech.com/
The Company Started in 1989 as a PROCESS ENGINEERING COMPANY & is today one of the most accomplished and diversified business houses in India having head office in Mumbai , branch office at Hyderabad. At NILSAN Nishotech we have two SBU’S SEPTECH & EPMG. The Group’s success has been driven by the company’s commitment to delivering innovation and excellence. Through the consistent application of this commitment and a century of ethical business conduct, Nilsan Nishotech has earned an unparalleled reputation for trust a,nd reliability.
In 23 years, NILSAN Nishotech is the first company in India to develop the technology to support Pharma, Bio-Pharma , Sugar , Food & Healthcare customers; this spirit of innovation has continued throughout the organization’s history. Today NILSAN Nishotech is delivering exciting engineering innovative solutions across a spectrum of businesses. The company’s pursuit of excellence is equally well established and enduring. NILSAN Nishotech’s management understands that the company’s greatest asset is the trust and faith that customers have reposed in it, and recognizes that the company must continue to earn this trust. This translates to the organization delivering outstanding quality and value in everything it does. We have Overseas association with French Company Novasep (Chromatography Columns) , Austar –China (RO+EDI Skid) , Ziemann –India (Tanks) , DrM – Switzerland (Candle Filtration System) for which we stand one point contact in India.
Sterile Process Piping, Separation Technologies, Pharma Water Technologies
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in…
Alexandre Williams, founder and managing director of Athena, an international company with an Indian manufacturing basis specialized in life cycle products, provides insights into some key trends shaping India’s pharmaceutical…
As the founder and chairman of Alves Group, a key Indian player in medical devices with an extensive portfolio, Randolph Alves shares the challenges India needs to overcome to remain…
Dharmesh Shah, managing director of BDR Pharmaceuticals, a company with a strong expertise in oncology, intensive care, and other therapeutic areas, provides us with an insightful overview of the main…
For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India still stands as a land of opportunity for a variety of reasons. Novartis India…
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities…
Nikhil Masurkar, executive director of Entod Pharmaceuticals, talks about the company’s ambition to invest in stem cell research and become market leaders in the field of ophthalmology in ten years’…
Manni Kantipudi, CEO of GVK BIO, talks about the evolution of the company, which he took from USD 20 million to its current USD 120 million, its future, its strategic…
R.S. Subramanian, country manager and Sandeep Juneja, vice president – Sales and Marketing, DHL Express India, explain why the world’s leading express logistics company is a trusted and accountable service…
A passionate advocate for Indian patients, Sanjiv Navangul, managing director of Janssen India, discusses the company’s public health work in the field of tuberculosis (TB) and multi-drug resistant TB (MDR-TB)…
A strong advocate for quality, Dilip Surana, chairman and managing director of Micro Labs, explains how the company’s strong focus on the quality of its products and move to specialty…
Amit Mookim, IQVIA’s general manager for South Asia, discusses the major trends impacting the Indian pharmaceutical market and how Indian companies are rethinking their commercial strategies and becoming more specialized…
See our Cookie Privacy Policy Here
